ASX/Media Release

13 November 2017

Investor Presentation

Sydney, 13 November 2017: Medical dermatology company Botanix Pharmaceuticals Limited (ASX:BOT, “Botanix” or the “Company”) is pleased to release an updated investor presentation, to be presented at the Botanix AGM in Perth (Tuesday 14 November) and meetings with investors and brokers as part of a non-deal roadshow across Australia in the coming weeks.

This investor presentation is being used to provide an update on the Company’s key activities including its: rapid operational progress over the last 12 months; lead clinical development program (BTX 1503) for acne; dermatitis clinical program (BTX 1204); development of other pipeline products; Permetrex™ collaborations and key milestones over the near to medium term.

About Botanix Pharmaceuticals
Botanix Pharmaceuticals is a clinical stage medical dermatology company, which is dedicated to developing next generation therapeutics for the treatment of serious skin diseases. Our mission is to improve the lives of patients battling acne, psoriasis and atopic dermatitis, by providing new treatment options for conditions that currently are inadequately addressed, or are treated with therapeutics that are burdened with side effects profiles. Botanix is harnessing the untapped potential of a synthetic active pharmaceutical ingredient, known as cannabidiol, which has a well-established safety profile. Botanix has successfully completed its first-in-man studies with BTX 1503 and is currently conducting a follow-on clinical trial with acne patients in 2H 2017. The Company has an exclusive license to use a proprietary drug delivery system (Permetrex™) for direct skin delivery of active pharmaceuticals in all skin diseases and plans to progress the development of BTX 1503 for acne and its pipeline of other Permetrex™ enabled products alone, or in collaboration with partners.

For more information on Botanix, please visit www.botanixpharma.com or follow us on Twitter @Botanixpharma.

For more information, please contact:

General enquiries
Matt Callahan
Botanix Pharmaceuticals Ltd
Executive Director
P: +1 215 767 4184
E: mcallahan@botanixpharma.com

Investor Relations
Joel Seah
Vesparum Capital
P: +61 3 8542 4800
E: botanixpharma@vesparum.com

Media enquiries
Harrison Polites
MC Partners
P: +61 409 623 618
E: harrison.polites@mcpartners.com.au
Botanix is one of the most compelling emerging companies on the ASX

**Dermatology Focused**
- Targeting a **multi-billion dollar market for acne therapeutics** with no new products approved in the last 20 years
- Not typical biotech – much **faster development pathway** for dermatology products, **drives lower costs** and much **quicker timeline to approval**

**Novel Approach**
- Lead products based on synthetic form of well-studied drug “cannabidiol” - **greatly enhances the probability of clinical and regulatory success**
- **Exclusive global rights to use Permetrex™** delivery technology for all skin diseases, with **potential to deliver near term partnerships and revenues**

**Experienced Team**
- Predominantly US based leadership team with **20+ FDA approvals** between them
- Advanced lead product from formulation to successful clinical trial **within 12 months** and **advanced second product into clinic within 18 months**
Corporate overview

Medical dermatology company with a clear path to commercialisation and a highly aligned Board and management team

<table>
<thead>
<tr>
<th>Trading information</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Share price (9-Nov-17)</td>
<td>A$0.050</td>
</tr>
<tr>
<td>52 week low / high</td>
<td>A$0.039 / A$0.072</td>
</tr>
<tr>
<td>Shares outstanding¹²</td>
<td>543.1</td>
</tr>
<tr>
<td>Market capitalisation</td>
<td>A$27.2m</td>
</tr>
<tr>
<td>Cash (as at 30-Sep-17)</td>
<td>A$4.2m</td>
</tr>
<tr>
<td>Debt (as at 30-Sep-17)</td>
<td>-</td>
</tr>
<tr>
<td>Enterprise value</td>
<td>A$22.9m</td>
</tr>
</tbody>
</table>

| Top shareholders (Nov 2017)             |       |
| Shareholder                              | %     |
| Matthew Callahan – Executive Director    | 13.0  |
| Caperi Pty Ltd – Co-founder              | 13.0  |
| Board and management (excl. shareholders above) | 3.7   |

Source: IRESS
1. Includes 156.5m fully paid ordinary shares subject to escrow until 15 July 2018
2. Excludes 47.9m unlisted options with exercise price range of A$0.03 - A$0.07 and expiry date range of Jan 2018 to May 2020
Senior leadership: track record of success

Proven industry professionals with experience in rapid development of pharmaceuticals

Mr Matthew Callahan
Executive Director
- Developed 3 products to date that have received FDA approval, 1 pending approval
- Previous investment director of 2 venture capital firms investing in life sciences

Dr Bill Bosch
Executive Director
- 6 FDA approved products and inventor of the iCeutica SoluMatrix Technology
- Founder of NanoSystems and co-inventor of drug delivery technology NanoCrystal

Dr Michael Thurn
Chief Operating Officer
- Extensive start up life sciences experience across a range of technology platforms
- Previous MD of Spinifex Pharmaceutical, which sold to Novartis for A$700m

Mr Mark Davis
VP Clinical and regulatory
- 30 years clinical experience with 19 FDA approved products across dermatology
- Former clinical lead with Medicis and Connetics and FDA experience with cannabidiol

20+ FDA approved products

Botanix Pharmaceuticals Ltd.
Clinical programs with near term milestones

Two programs in patient studies, with partnerships on the Permetrex™ technology to augment revenue and news flow in the near term

<table>
<thead>
<tr>
<th>Product Candidate</th>
<th>Indication</th>
<th>Pre-Clin</th>
<th>Ph I</th>
<th>Ph Ib</th>
<th>Ph II</th>
<th>Next milestones</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Synthetic Cannabidiol</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BTX 1503</td>
<td>Moderate to Severe Acne</td>
<td></td>
<td></td>
<td></td>
<td>Ph Ib patient data available</td>
<td>1Q CY2018</td>
</tr>
<tr>
<td>BTX 1204</td>
<td>Atopic Dermatitis</td>
<td></td>
<td></td>
<td></td>
<td>Phase Ib patient data available</td>
<td>1H CY2018</td>
</tr>
<tr>
<td>BTX 1308</td>
<td>Psoriasis</td>
<td></td>
<td></td>
<td></td>
<td>Pre-clinical testing</td>
<td>1Q CY2018</td>
</tr>
<tr>
<td><strong>Permetrex™ Enabled</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BTX 1701</td>
<td>Acne Cleanser</td>
<td></td>
<td></td>
<td></td>
<td>Pilot patient study start</td>
<td>1Q CY2018</td>
</tr>
<tr>
<td>BTX 1801</td>
<td>Not disclosed</td>
<td></td>
<td></td>
<td></td>
<td>Formulation complete</td>
<td>4Q CY2017</td>
</tr>
</tbody>
</table>

Botanix Pharmaceuticals Ltd.
Why are we focused first on acne?

Global prescription market expected to grow to >US$4.5bn by 2018

Global prescription acne product revenues (topical and oral treatments)

Value of the global acne prescription market is expected to reach US$4.5bn by 2018

Annual topical prescription acne product revenues

Top branded acne products containing only generic drugs have achieved revenues of up to >US$300m p.a.

Large demand with limited recent product development

- **50 million patients** (in the US alone) used an acne product in 2015
- No new chemical entities have been approved by the FDA in the last 20 years for the treatment of acne
- Only “new” products launched were combinations of old drugs in new formulations or packaging

---

1. BCC Research, May 2013. Skin Disease Treatment and Global Markets
2. Symphony Health Solutions, Pharmaceutical Audit Suite for 2012 as reported in Demira S1
How does BTX 1503 work to treat acne?

BTX 1503 utilises synthetic cannabidiol combined with a novel skin delivery technology

- Attacks *P. Acnes* bacteria
- Switches off excess production of sebum
- Retards formation of sebum “plugs”
- Reduces inflammation

BTX 1503 Phase Ia clinical trial results

BTX 1503 utilises synthetic cannabidiol combined with a novel skin delivery technology

Safety, Tolerability and Irritation

- BTX 1503 displayed an excellent safety profile
- Little to no evidence of skin irritation observed across all dose levels
- No severe adverse events recorded and the incidence of other adverse events was very low
- Most common adverse event was mild dryness - consistent with the mechanism of action of BTX 1503


Effective delivery into and deposition in the skin

Permetrex™ + Synthetic Cannabidiol

Significant deposition into the skin – very little into the blood stream
BTX 1503 market positioning

BTX 1503 has the potential to be the market leading branded product for acne treatment, with no undesirable side effects

**Market landscape for acne treatments**¹

- BTX 1503 has multiple mechanisms of action that address the key pathogenic factors that cause acne – not just symptoms
- While systematic therapies (i.e. Accutane) may inhibit sebum (skin-oil) production, its use is limited by very serious side-effects
- Significant unmet need for an effective therapy that targets the causes of acne but does not have the undesirable side effects
- Leading existing treatments fetched annual revenues in the range of US$700m-US$800m when they were patented products
- BTX 1503’s patent protection is a significant competitive advantage, as all other treatments below are now generic products

<table>
<thead>
<tr>
<th>Method of action</th>
<th>BTX 1503</th>
<th>Clindamycin</th>
<th>Tretinoin</th>
<th>Adapalene</th>
<th>Minocycline</th>
<th>Erythromycin</th>
<th>Accutane</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reduces excessive sebum (skin oil) production</td>
<td>✓</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Anti-inflammatory</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Anti-bacterial</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Topical (applied to a specific area of the body)</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Minimal side effects</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Patent protected (not a generic product)</td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
<td>✓</td>
<td></td>
<td>✓</td>
</tr>
</tbody>
</table>

¹ Subject to successful development and approvals
BTX 1503 acne patient study underway

Botanix is pursuing a rapid clinical development strategy to minimise product commercialisation timing and accelerate to first revenues

- Phase Ib acne pilot study currently underway, with study enrolment complete in 4Q CY2017 and data expected to be available in 1Q CY2018
- In October 2017, Botanix successfully completed a Pre-IND meeting with the FDA for BTX 1503 acne product – FDA confirmed the proposed development plan and data package to allow Phase 2 clinical development in the US
- BTX 1503 well placed to commence FDA regulated Phase 2 clinical study in 1H CY2018

BTX 1503 indicative clinical timeline (CY)

- Pre-IND Meeting FDA
- Phase Ib acne pilot study
- File IND for FDA regulated Phase II trial
- IND ‘Approval’ for Phase II
- Phase II multi-centre acne patient trial

Milestones

<table>
<thead>
<tr>
<th>3Q 2017</th>
<th>4Q 2017</th>
<th>1Q 2018</th>
<th>2Q 2018</th>
<th>3Q 2018</th>
<th>4Q 2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pre-IND Meeting FDA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase Ib acne pilot study</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>File IND for FDA regulated Phase II trial</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IND ‘Approval’ for Phase II</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phase II multi-centre acne patient trial</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Botanix Pharmaceuticals Ltd.
Permetrex™ skin delivery technology

Permetrex™ delivers high doses of synthetic cannabidiol directly into the layers of the skin – oral administration only delivers ~6% to the blood stream and even less to the skin.

Botanix holds the exclusive rights to utilise Permetrex™ for all drugs that treat skin diseases.
BTX 1204 for atopic dermatitis

Phase Ib patient study commenced in late October, with data planned for 2Q 2018

Market overview

BTX 1204: dermatitis

- **Target market:** US patient incidence estimated to be 25 million people (10% to 18% of children)

- **Market size:** estimated annual cost of treating atopic dermatitis in the US is ~US$4bn

- **Current issues:** most treatments on the market (i.e. steroids) only address the symptoms

BTX 1204 indicative clinical timeline (CY)

- Received Human Research Ethics Committee approval recently (late October 2017) to commence Phase Ib dermatitis patient study

- Enrolment of patients to commence in 4Q CY2017, across 4 leading dermatology clinics in Australia

- Expected study completion in 1H CY2018 – Phase Ib study focused on assessing safety and indications of efficacy of BTX 1204

- Study demonstrates Botanix’s ability to accelerate the addition of clinical programs by leveraging previous clinical data from acne program

---

BTX 1204 for atopic dermatitis

Phase Ib patient study commenced in late October, with data planned for 2Q 2018

Market overview

BTX 1204: dermatitis

- **Target market:** US patient incidence estimated to be 25 million people (10% to 18% of children)

- **Market size:** estimated annual cost of treating atopic dermatitis in the US is ~US$4bn

- **Current issues:** most treatments on the market (i.e. steroids) only address the symptoms

BTX 1204 indicative clinical timeline (CY)

- Received Human Research Ethics Committee approval recently (late October 2017) to commence Phase Ib dermatitis patient study

- Enrolment of patients to commence in 4Q CY2017, across 4 leading dermatology clinics in Australia

- Expected study completion in 1H CY2018 – Phase Ib study focused on assessing safety and indications of efficacy of BTX 1204

- Study demonstrates Botanix’s ability to accelerate the addition of clinical programs by leveraging previous clinical data from acne program
BTX 1204 positioning and opportunity

Targeting efficacy improvements with much better safety profile than monoclonal antibodies and high potency steroids

Ideal Profile:
- Efficacy similar to mid-potency steroids
- Safety profile that allows long term use

Market comparable
- **Product:** Crisaborole® - a non-steroidal anti-inflammatory PDE-4 inhibitor
- **Data:** Phase 3 studies showing a pooled improvement of ~10% over placebo
- **Opportunity:** Forecast to generate sales of ~US$750m p.a.
- **Deal:** Pfizer acquired Anacor for US$5.2bn in late 2016
Development pipeline

Development pipeline also includes other synthetic cannabidiol and Permetrex™ enabled products targeting key dermatology markets.

**BTX 1308: psoriasis**
- **Target market:** ~7.5m Americans have psoriasis (most have plaque psoriasis)
- **Market size:** estimated annual costs of injectable biologic treatments in the US is ~US$20bn p.a.
- **Current issues:** biologic drugs are very expensive have serious side effect issues (including lymphoma)

*Intend to undertake study in pre-clinical skin models in 1Q CY2018*

**BTX 1701: mild acne**
- **Target market:** ~50m Americans have acne – symptoms vary in seriousness
- **Market size:** ~US$1.5bn p.a. – pilot study validated prospective activity vs. leading competitor
- **Current issues:** existing products use high levels of preservatives or alcohol which dry and irritate skin

*Intend to undertake small patient study in 1Q CY2018*

These products leverage data from the BTX 1503 synthetic cannabidiol clinical program and/or the Permetrex™ delivery system studies.
Permetrex™ collaborations advancing

Third party dermatology companies working with Botanix to solve drug delivery problems for their molecules

**Early collaborations leading to license discussions**

- Many companies have challenges formulating drugs for delivery into the skin
- Botanix is working with multiple parties to test application of Permetrex™ technology to solve problems that have arisen in clinical studies
- Engagement generally starts as fee-for-service by Botanix
- License trigger is generally proof of concept human study
- Traditional license structure likely (upfront payments, milestones, royalties)
Achievements since listing in July 2016

Botanix has advanced 2 products into the clinic within 18 months, progressed 3 pipeline products and leveraged Permetrex™ technology into a number of collaborations.

<table>
<thead>
<tr>
<th>Clinical Programs</th>
<th>BTX 1503 Acne</th>
<th>BTX 1204 Dermatitis</th>
<th>BTX 1308 Psoriasis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Successful Phase 1a clinical study</td>
<td>First acne patient studies underway</td>
<td>Successful Pre-IND meeting with FDA</td>
</tr>
<tr>
<td></td>
<td>Pre-clinical and formulation completed</td>
<td>Leveraged BTX 1503 data to skip Phase 1a</td>
<td>First dermatitis patient studies underway</td>
</tr>
<tr>
<td>Permetrex™ Pipeline</td>
<td>BTX 1701 Acne Cleanser</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Pilot patient study completed</td>
<td>Commercial review undertaken</td>
<td>Prep for patient study underway</td>
</tr>
<tr>
<td>General</td>
<td>BTX 1801 + Permetrex™</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>New product leveraging Permetrex</td>
<td>Collaborations with derm companies</td>
<td>More pipeline products in development</td>
</tr>
<tr>
<td></td>
<td>Established US and Aus operations</td>
<td>Built experienced team in dermatology</td>
<td>Rapid advancement – solid planning</td>
</tr>
</tbody>
</table>

Botanix Pharmaceuticals Ltd.
Near term key catalysts

Significant operational milestones expected over the next 12 months, as Botanix advances key products, broadens pipeline and undertakes corporate development.

<table>
<thead>
<tr>
<th>Indicative activities and milestones</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>BTX 1503 Acne</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>BTX 1204 Dermatitis</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>BTX 1308 Psoriasis</strong></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td><strong>BTX 1701</strong></td>
</tr>
<tr>
<td><strong>Permetrex™</strong></td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>
Appendix
Botanix Board of Directors

Highly credentialed Board of Directors with a proven record of building and leading successful pharmaceuticals businesses

Graham Griffiths
Chairman
Appointed July 2016

- 40 years executive experience in technology based companies, across sales, marketing and product development
- Former Managing Director of ipernica, responsible for acquisition and commercialisation of nearmap.com (ASX:NEA)
- Non-Executive Director of Pointerra (ASX:3DP), iperative and NGIS Australia

Matthew Callahan
Executive Director
Appointed July 2016

- Founding CEO of iCeutica and Churchill Pharmaceuticals
- Co-inventor of iCeutica’s SoluMatrix Technology
- Developed 3 FDA approved products
- Investment director at 2 venture capital firms
- 20 years experience in legal, IP and investment management
- Director of Orthocell (ASX:OCC) and Glycan Bioscience LLC

Dr Bill Bosch
Executive Director
Appointed July 2016

- 20 years experience in the pharmaceutical industry
- Co-inventor of iCeutica’s SoluMatrix Technology
- Developed 6 FDA approved products
- Developed 4 commercial nanotechnology products at Elan Corporation
- Co-founder of NanoSystems LLC and co-inventor of NanoCrystal Technology

Rob Towner
Director
Appointed July 2016

- 20 years corporate advisory experience
- Founder and sole director of Cornerstone Corporate
- Founding Executive Director of bioMD
- bioMD merged with Allied Health Care in 2011 to form Admedus (ASX:AHZ, $200m market capitalisation)
- Executive Director of Triangle Energy (ASX:TEG)

Commercialisation
Corporate and IP
Manufacturing and IP
Financing and capital markets
**Botanix executive management**

Highly credentialed clinical development team with extensive expertise in leading novel products through clinical and regulatory development

**Mr Mark Davis**
**VP Clinical and Regulatory**
- 30 years of clinical experience with 19 FDA approved products
- Unique experience with cannabidiol through Insy
- Former clinical lead with Medicis and Connetics

**Dr Michael Thurn**
**Chief Operating Officer**
- Extensive start up life sciences experience across a range of technology platforms
- +20 years experience in drug regulation, drug discovery, pre-clinical and clinical
- Previous Managing Director of Spinifex Pharmaceuticals

**Dr Gene Cooper**
**Consultant**
- 40 years pharmaceutical experience
- 10 FDA approved products
- Expert in skin delivery
- Inventor of Permetrex™

**Dr Joel Gelfand**
**Medical Director of Clinical Studies**
- Professor of Dermatology at the University of Pennsylvania
- Expert in skin disease and clinical trial management

**Professor James Leyden**
**Scientific Adviser**
- Professor of Dermatology at the University of Pennsylvania
- World leading acne and skin specialist

**Professor Diane Thiboutot**
**Scientific Adviser**
- Professor of Dermatology at Pennsylvania State University
- Researcher in acne and rosacea
- Pre-clinical and clinical trials services provider

---

Botanix Pharmaceuticals Ltd.
Strategic and commercialisation focus

Primary strategy is commercialising BTX 1503, advancing BTX 1204, explore licensing opportunities for Permetrex™ and development of a supportive product pipeline

- **BTX 1503**
  - Acne

- **BTX 1204**
  - Dermatitis

- **Permetrex™**
  - Delivery technology

- **BTX 1308**
  - Psoriasis

- **BTX 1701**
  - Acne cleanser

**Active pharmaceutical**

- Cannabidiol

**Near term focus**

- Clinical development and commercialisation
  - Accelerating clinical development through undertaking clinical studies in Australia, leading into a US FDA approval

**Near to medium term focus**

- Permetrex™ licensing
  - Licensing Permetrex™ delivery system to strategic parties, to generate potential near term revenue

**Medium to long term focus**

- Other pipeline products
  - Leverage data from BTX 1503 program to accelerate development of new products in psoriasis and acne cleanser
Recent corporate and product development

Recent developments have provided a strong platform for Botanix to accelerate its clinical development program

Key milestones over the last 12 months

<table>
<thead>
<tr>
<th>Date</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jul 2016 to Feb 2017</td>
<td>Key staff hires across key business divisions</td>
</tr>
<tr>
<td>Feb 2017</td>
<td>Completed expansion of Permetrex™ license to cover the delivery of drug actives used in treating skin diseases</td>
</tr>
<tr>
<td>Mar 2017</td>
<td>Received DEA approval for export and import of synthetic cannabidiol for clinical studies</td>
</tr>
<tr>
<td>Apr 2017</td>
<td>Completed A$7.4m oversubscribed placement</td>
</tr>
<tr>
<td>Aug 2017</td>
<td>Commence BTX 1503 Phase Ib Acne patient study</td>
</tr>
<tr>
<td>Oct 2017</td>
<td>Received ethics approval for BTX 1204 and commence dermatitis study</td>
</tr>
<tr>
<td>Nov 2016</td>
<td>Manufactured BTX 1503 trial formulation using FDA quality components</td>
</tr>
<tr>
<td>Dec 2016</td>
<td>Completed first human safety and irritation study with Permetrex™</td>
</tr>
<tr>
<td>Mar 2017</td>
<td>Received ethics approval for BTX 1503, and commenced first clinical study</td>
</tr>
<tr>
<td>June 2017</td>
<td>Completion of successful pilot study for BTX 1701 facial cleanser</td>
</tr>
<tr>
<td>July 2017</td>
<td>Successful completion of Phase I clinical study for BTX 1503</td>
</tr>
<tr>
<td>Oct 2017</td>
<td>FDA clears development path for BTX 1503</td>
</tr>
</tbody>
</table>

Formulation → Safety and Efficacy → Proof of Concept

Key milestones achieved
# Accelerated development timeline

Botanix is executing on an efficient, more economical and less risky clinical development strategy compared to traditional pharmaceutical development pathways.

## Botanix’s accelerated clinical timeline

<table>
<thead>
<tr>
<th>Phases</th>
<th>Traditional process</th>
<th>Botanix approach</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Costs (est.)</td>
<td>Costs (est.)</td>
</tr>
<tr>
<td>Discovery and pre-clinical</td>
<td>~$430m</td>
<td>~$1m</td>
</tr>
<tr>
<td>Investigational New Drug filing</td>
<td>~$1m</td>
<td>~6 months</td>
</tr>
<tr>
<td>Phase I clinical</td>
<td>~$25m</td>
<td>~$2m</td>
</tr>
<tr>
<td></td>
<td>~7 years</td>
<td>~6 months</td>
</tr>
<tr>
<td>Phase II clinical</td>
<td>~$35m</td>
<td>~$7m</td>
</tr>
<tr>
<td></td>
<td>~7 years</td>
<td>~28 months</td>
</tr>
<tr>
<td>Phase III clinical</td>
<td>~$54m</td>
<td>~$23m</td>
</tr>
<tr>
<td>New Drug Application</td>
<td>~$5m</td>
<td>~$2m</td>
</tr>
<tr>
<td></td>
<td>~2 years</td>
<td>~12 months</td>
</tr>
<tr>
<td>Total</td>
<td>~$460m</td>
<td>~$35m</td>
</tr>
<tr>
<td></td>
<td>~14 years</td>
<td>~4 years</td>
</tr>
</tbody>
</table>

**Proven ability to execute: Achieved since listing**

- Accelerated development timeline, due to:
  - Minimal pre-clinical development due to known safety profile of cannabidiol
  - Dermatology studies tend to be shorter in duration and require smaller study populations
  - **Objective measurements of efficacy** (end points are typically visual assessments)
  - Opportunity to generate near term revenue from potential licensing agreements for Permetrex™
  - In house expertise ensures clinical trials are appropriately designed and efficiently implemented
  - Known safety profile increases probability of successful clinical development
Commercialisation strategy

Botanix’s focused and accelerated timeline to product commercialisation results in significant potential value uplift

Efficient commercialisation path with multiple options

- Continued clinical development success is reflected in significant value uplift after each successive phase
  - Typically monetised via licensing, partnering and/or sale/merger opportunities
  - Additional indications can be partnered while pursuing acne focus

- Potential future revenue streams:
  - Product licensing agreements
  - Partnership with strategic parties
  - Product sales revenue

- Significant value uplift potential at the completion of each phase of development (as evidenced by recent dermatology transactions)

- Phase I (< 12 months)
- Phase II (~ 12 months)
- Phase III (~ 24 months)
- Investment decision
  - License, partner and/or sale opportunities
Botanix has protected its suite of development products through various patent applications across key global markets.

- Botanix currently has 12 patent applications across 6 different patent families.
- Patents applications cover lead acne product and other Permetrex™ enabled products.
- Patent protection targeted at key geographic regions with large and viable dermatology markets (i.e., initially filed in US and Australia, but following into the EU, UK, Japan, India, China, South America and other jurisdictions in National phase).
- Botanix positioned as the leading player in the sector – underpinned by substantial volumes of proprietary knowledge, manufacturing know-how and trade secrets.
- Additional IP opportunities will be pursued on each Permetrex™ product developed internally or with partners.

Initial patent applications protecting BTX 1503

Expanded patent applications for BTX 1503 and other Permetrex™ enabled products
Recent dermatology transactions

Licensing and partnering transactions are potential monetisation options before product sales, with value increasing significantly as a product progress through the FDA process.

**Dermatology transactions**

<table>
<thead>
<tr>
<th>Deal date</th>
<th>Deal type</th>
<th>Licensee/Acquirer</th>
<th>Licensor/Target</th>
<th>Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sep 2015</td>
<td>License</td>
<td>VALEANT</td>
<td>Allergan</td>
<td>In Phase III</td>
</tr>
<tr>
<td>Dec 2016</td>
<td>License</td>
<td>PURDUE</td>
<td>(rights)</td>
<td>Completed Phase I</td>
</tr>
<tr>
<td>Jan 2016</td>
<td>Corporate</td>
<td>Allergan</td>
<td>sienna</td>
<td>In pre-clinical development</td>
</tr>
<tr>
<td>Dec 2016</td>
<td>Corporate</td>
<td>Allergan</td>
<td>Allergan</td>
<td>In pre-clinical development / Phase IIb</td>
</tr>
<tr>
<td>Oct 2016</td>
<td>Corporate</td>
<td>AstraZeneca</td>
<td>anterios</td>
<td>In Phase II</td>
</tr>
<tr>
<td>Apr 2016</td>
<td>Asset/business</td>
<td>exicure</td>
<td>Vitae</td>
<td>On market</td>
</tr>
<tr>
<td>May 2016</td>
<td>Corporate</td>
<td>(rights)</td>
<td>(global dermatology business)</td>
<td>Completing Phase III</td>
</tr>
</tbody>
</table>

**Source:** Bloomberg, Company disclosure

Total upfront and milestone payments could exceed these figures in aggregate: US$445m, US$790m, US$90m, US$150m, US$639m, US$770m, US$5,200m.
**BTX 1503 key advantage: synthetic material**

Use of synthetic cannabidiol greatly increases the chance of clinical success and regulatory approval - at a much lower COGS than naturally extracted material.

<table>
<thead>
<tr>
<th>Synthetic cannabidiol</th>
<th>Naturally extracted cannabidiol</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 chemical</td>
<td>100+ chemicals</td>
</tr>
<tr>
<td>100% pure</td>
<td>Multiple impurities (anything above 0.05% needs to be identified and tested)</td>
</tr>
<tr>
<td>Scaled up to 50kg</td>
<td>Scaled up to &lt;1kg</td>
</tr>
<tr>
<td>No additional compliance required</td>
<td>Must comply with FDA’s “Botanical Drug Development Guidance for Industry” ¹</td>
</tr>
</tbody>
</table>

---

Disclaimer

This presentation prepared by Botanix Pharmaceuticals Limited ("Company") does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issue or transfer of the securities referred to in this presentation in any jurisdiction in contravention of applicable law. Persons needing advice should consult their stockbroker, bank manager, solicitor, accountant or other independent financial advisor.

This document is confidential and has been made available in confidence. It may not be reproduced, disclosed to third parties or made public in any way or used for any purpose other than in connection with the proposed investment opportunity without the express written permission of the Company.

This presentation should not be relied upon as a representation of any matter that an advisor or potential investor should consider in evaluating the Company. The Company and its related bodies corporate or any of its directors, agents, officers or employees do not make any representation or warranty, express or implied, as to the accuracy or completeness of any information, statements or representations contained in this presentation, and they do not accept any liability whatsoever (including in negligence) for any information, representation or statement made in or omitted from this presentation.

This document contains certain forward looking statements which involve known and unknown risks, delays and uncertainties not under the Company’s control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward looking statements. The Company makes no representation or warranty, express or implied, as to or endorsement of the accuracy or completeness of any information, statements or representations contained in this presentation with respect to the Company.

It is acknowledged that the Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.